Diginex's October Ballot: The $1.05 Billion Question Hanging Over a 600 Million Share Pile
Published on 09/02/2026 at 11:01 | Editorial boerse-global.de
The arithmetic has become brutally simple for Diginex shareholders. A company that generated $3.6 million in annual revenue is attempting to absorb a business valued at $1.05 billion, and the currency for that ambition is printed in new equity. Roughly 600 million additional shares have been added to the deal's structure, leaving existing holders facing an 86 percent dilution that the market has already begun to price in — weeks before the extraordinary general meeting scheduled for October 8.
The stock's slide from its late-July peak now approaches 52 percent, and the pattern behind that decline is consistent: every fresh piece of news tied to the Resulticks acquisition has pushed the shares lower rather than higher. The week around August 15 brought a 24.6 percent drop alone, triggered by the revised deal terms that introduced the extra share issuance.
A Deal Reshaped Under Pressure
The transaction has already undergone significant surgery. Originally structured at $1.5 billion with roughly 1.13 billion new Diginex shares priced at $1.32 each, the acquisition has since been scaled back to $1.05 billion — but at the cost of a far heavier equity component. The company has also had to secure $70 million in private financing commitments as the deal's long-stop date slipped from July 31 to August 12, a sequence of extensions and renegotiations that speaks more to strain than stability.
When your company's future depends on getting the details right, the same principle applies to workplace safety — a single overlooked risk can have serious consequences. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
What makes the dilution particularly painful is the timing. Management changes have been rolling out in parallel — Jan-Jaap Verhoeve was appointed Chief Commercial Officer in early July, part of a broader leadership reshuffle at both Diginex and Resulticks that suggests integration planning is already underway. The June launch of Risk-To-Remedy, an end-to-end due-diligence product for the supply-chain business, shows the company attempting to maintain organic momentum even as its center of gravity shifts toward Resulticks' customer-data and marketing analytics.
The Operating Reality Behind the Pivot
The financials explain why Diginex feels compelled to pursue this transformation. Revenue for the fiscal year ended March 31 climbed 77 percent to $3.6 million, yet the net loss ballooned to $31.1 million from $5.2 million the prior year. Adjusted EBITDA losses reached $13.0 million, compounded by a $7.0 million goodwill impairment. The balance sheet offers some comfort — zero debt, $4.9 million in cash, and net assets of $20.3 million — but that cushion looks more like transitional padding than evidence of operational health when losses run more than eight times revenue.
The technical picture offers little reassurance. Resistance between $1.77 and $1.90 proved immovable, and the stock now trades at $1.17 following a 1.7 percent decline on the day. The weekly loss stands at 10 percent, the monthly figure at 20 percent. With a relative strength index of 39.4, the stock isn't oversold so much as directionless, while annualized volatility of 107 percent captures just how jittery trading has become. At a market capitalization of roughly €30.1 million, Diginex now sits firmly in micro-cap territory, where even modest trading volumes can produce outsized swings.
What October Will Decide
The extraordinary general meeting now looms as the moment of reckoning. Shareholders will be asked to approve a structure that leaves them holding a fraction of the combined entity — a vote that will determine whether the company's transformation proceeds as planned or collapses under the weight of its own financing mechanics. Until then, the absence of meaningful analyst coverage leaves the stock without a corrective force against the prevailing negative momentum, and the uncertainty alone is likely to keep pressure on the shares.
